Ramipril/hydrochlorothiazide

Drug Profile

Ramipril/hydrochlorothiazide

Alternative Names: Altace HCT; Hydrochlorothiazide/ramipril; Triatec HCT

Latest Information Update: 05 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Antihypertensives; Benzothiadiazines; Heterocyclic bicyclo compounds
  • Mechanism of Action ACE inhibitors; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 04 Mar 2015 Ramipril/hydrochlorothiazide licensed to Valeant Canada in Canada
  • 01 Mar 2011 King Pharmaceuticals has been acquired and merged into Pfizer
  • 01 Mar 2007 Phase III development is ongoing in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top